miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression Corrigendum in /10.3892/mmr.2022.12738 Retraction in /10.3892/mmr.2025.13475

Chen,Bin; Zhu,Akao; Tian,Lei; Xin,Ying; Liu,Xinchun; Peng,Yunpeng; Zhang,Jingjing; Miao,Yi; Wei,Jishu

doi:10.3892/mmr.2018.8941

July-2018 Volume 18 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2018 Volume 18 Issue 1

Full Size Image

Article Open Access

miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression

Corrigendum in: /10.3892/mmr.2022.12738

Retraction in: /10.3892/mmr.2025.13475

Authors:
- Bin Chen
- Akao Zhu
- Lei Tian
- Ying Xin
- Xinchun Liu
- Yunpeng Peng
- Jingjing Zhang
- Yi Miao
- Jishu Wei
View Affiliations / Copyright

Affiliations: Hepatopancreatobiliary Surgery Department, The Affiliated Hangzhou Hospital of Nanjing Medical University, Hangzhou, Zhejiang 310006, P.R. China, The Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Thyroid Breast Surgery Department, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 105-112
|
Published online on: April 27, 2018

https://doi.org/10.3892/mmr.2018.8941
Expand metrics +

Abstract

The present study aimed to explore the effects and underlying mechanisms of microRNA (miR)‑23a on pancreatic cancer (PC) cells progression. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were used to detect the mRNA and protein miR‑23a and PLK‑1 level. Cell viability, cell cycle, migration and invasion assasy, and in vivo tumorigenicity assay were used to investigate the effects of miR‑204. Further luciferase reporter assay was used to explore the mechanisms contributing to miR‑204 effects. It was observed that miR‑23a expression was upregulated and negatively associated with polo‑like kinase‑1 (PLK‑1) expression in human PC tissues. PLK‑1 was a direct target of miR‑23a in PC cells. Functional analysis demonstrated that miR‑23a overexpression suppressed cell proliferation, inhibited cell migration and invasion and promoted cell apoptosis in vitro. When PC cells were transfected with has‑miR‑23a PLK‑1 was downregulated and its downstream molecules were deregulated, including decreased expression of B‑cell lymphoma‑2, cyclin B1 and vimentin, and increased expression of Bax and E‑cadherin. The inhibitory effect of miR‑23a on PC cell progression was observed in vivo tumor xenografts. The results of the study suggest that miR‑23a inhibits PC cell progression by directly targeting PLK‑1‑associated signaling and promoting miR‑23a expression may be a potential method for treating patients with PC.

View Figures

View References

1	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
2	Subramani R, Gangwani L, Nandy SB, Arumugam A, Chattopadhyay M and Lakshmanaswamy R: Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review). Int J Oncol. 47:1203–1210. 2015. View Article : Google Scholar : PubMed/NCBI
3	Yong FL, Wang CW, Roslani AC and Law CW: The involvement of miR-23a/APAF1 regulation axis in colorectal cancer. Int J Mol Sci. 15:11713–11729. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ma G, Dai W, Sang A, Yang X and Gao C: Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer. Int J Clin Exp Pathol. 7:8833–8840. 2014.PubMed/NCBI
5	Eissa S, Matboli M and Shehata HH: Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer. Transl Res. 165:417–427. 2015. View Article : Google Scholar : PubMed/NCBI
6	Koller K, Das S, Leuschner I, Korbelius M, Hoefler G and Guertl B: Identification of the transcription factor HOXB4 as a novel target of miR-23a. Genes Chromosomes Cancer. 52:709–715. 2013. View Article : Google Scholar : PubMed/NCBI
7	Piepoli A, Tavano F, Copetti M, Mazza T, Palumbo O, Panza A, di Mola FF, Pazienza V, Mazzoccoli G, Biscaglia G, et al: Mirna expression profiles identify drivers in colorectal and pancreatic cancers. PLoS One. 7:e336632012. View Article : Google Scholar : PubMed/NCBI
8	Liu N, Sun YY, Zhang XW, Chen S, Wang Y, Zhang ZX, Song SW, Qiu GB and Fu WN: Oncogenic miR-23a in pancreatic ductal adenocarcinogenesis via inhibiting APAF1. Dig Dis Sci. 60:2000–2008. 2015. View Article : Google Scholar : PubMed/NCBI
9	Liu X: Targeting polo-like kinases: A promising therapeutic approach for cancer treatment. Transl Oncol. 8:185–195. 2015. View Article : Google Scholar : PubMed/NCBI
10	Strebhardt K: Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 9:643–660. 2010. View Article : Google Scholar : PubMed/NCBI
11	Liu J, Lu KH, Liu ZL, Sun M, De W and Wang ZX: MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 12:5192012. View Article : Google Scholar : PubMed/NCBI
12	Xu C, Li S, Chen T, Hu H, Ding C, Xu Z, Chen J, Liu Z, Lei Z, Zhang HT, et al: miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer. Oncol Rep. 35:497–503. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhang C, Sun X, Ren Y, Lou Y, Zhou J, Liu M and Li D: Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells. Cancer Biol Ther. 13:1214–1220. 2012. View Article : Google Scholar : PubMed/NCBI
14	Raab M, Kappel S, Krämer A, Sanhaji M, Matthess Y, Kurunci-Csacsko E, Calzada-Wack J, Rathkolb B, Rozman J, Adler T, et al: Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells. Nat Commun. 2:3952011. View Article : Google Scholar : PubMed/NCBI
15	Weichert W, Schmidt M, Jacob J, Gekeler V, Langrehr J, Neuhaus P, Bahra M, Denkert C, Dietel M and Kristiansen G: Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 5:259–265. 2005. View Article : Google Scholar : PubMed/NCBI
16	Tian K, Di R and Wang L: MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma. Cancer Gene Ther. 22:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wang G, Li B, Fu Y, He M, Wang J, Peng S and Bai L: miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumour Biol. 36:4715–4721. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

miR‑23a suppresses pancreatic cancer cell progression by inhibiting PLK‑1 expression

Corrigendum in: /10.3892/mmr.2022.12738

Retraction in: /10.3892/mmr.2025.13475

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles